Sinovac Biotech Receives RMB 100 Million Loan To Produce H1N1 Vaccine
This article was originally published in PharmAsia News
Executive SummarySinovac Biotech, the only member in the influenza vaccine supply international task force from China, has signed the country's first influenza A (H1N1) vaccine production contract with the Beijing Centers for Disease Control and Prevention. From August, 5 million doses of the vaccine will be supplied to the city in three batches. To support Sinovac's production, the Bank of Beijing has provided the firm a loan of over RMB 100 million ($14.6 million), which exceeds the total loans Sinovac received from the bank in the past six years. (Click here for more - Chinese Language)
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.